S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:ERYP

ERYTECH Pharma (ERYP) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free ERYP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$3.10
▼
$3.10
50-Day Range
$4.19
▼
$5.08
52-Week Range
$0.30
▼
$1.47
Volume
N/A
Average Volume
93,510 shs
Market Capitalization
$105.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsHeadlinesSocial Media
ERYP stock logo

About ERYTECH Pharma Stock (NASDAQ:ERYP)

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

ERYP Stock News Headlines

February 21, 2024 | finanznachrichten.de
Phaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
January 19, 2024 | morningstar.com
Royalty Pharma PLC Class A RPRX
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
June 28, 2023 | finanznachrichten.de
Erytech Pharma S.A.: Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
June 28, 2023 | finance.yahoo.com
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
June 27, 2023 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital - June 26, 2023
June 26, 2023 | finance.yahoo.com
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
June 23, 2023 | finance.yahoo.com
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
June 20, 2023 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
June 15, 2023 | msn.com
Tech, Pharma Stocks Lead European Equities Higher in Thursday Trading
June 14, 2023 | finance.yahoo.com
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
June 13, 2023 | benzinga.com
Erytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes Closer
June 13, 2023 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023
June 12, 2023 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH Responds to Akkadian's Disinformation
June 12, 2023 | finance.yahoo.com
ERYTECH Responds to Akkadian’s Disinformation
June 5, 2023 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
June 5, 2023 | finance.yahoo.com
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
May 24, 2023 | finance.yahoo.com
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
May 24, 2023 | msn.com
Pharma Stocks Lead European Equities Sharply Lower in Wednesday Trading
May 23, 2023 | businesswire.com
PHERECYDES Announces the Availability of the Exemption Document Relating to the Proposed Combination With Erytech Pharma
May 23, 2023 | finance.yahoo.com
ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes
May 23, 2023 | msn.com
Pharma Stocks Lead European Equities Modestly Lower in Tuesday Trading
May 19, 2023 | msn.com
European Equities Rise in Friday Trading, Poised to End Week Higher
May 17, 2023 | msn.com
Pharma Stocks Weigh Down European Equities in Wednesday Trading
May 16, 2023 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _May 15, 2023
May 16, 2023 | msn.com
Pharma Stocks, Vodafone Lead European Equities Lower in Tuesday Trading
See More Headlines
Receive ERYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ERYP
CUSIP
N/A
CIK
1624422
Web
www.erytech.com
Phone
(347) 874-4438
Fax
33-4-78-75-56-29
Employees
49
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
3.65
Quick Ratio
3.65

Sales & Book Value

Annual Sales
$32.66 million
Price / Sales
3.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.80 per share
Price / Book
3.88

Miscellaneous

Outstanding Shares
34,120,000
Free Float
33,458,000
Market Cap
$105.77 million
Optionable
Not Optionable
Beta
2.69
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Gil Beyen M.B.A. (Age 61)
    CEO & Director
    Comp: $624.52k
  • Mr. Eric Soyer Ph.D. (Age 57)
    Deputy GM, CFO & COO
    Comp: $414.28k
  • Dr. Jérôme Bailly Pharm.D. (Age 44)
    Deputy GM of Operations, Chief Quality Officer & Qualified Person
    Comp: $270.47k
  • Naomi Eichenbaum
    Director Investor Relations
  • Ms. Anne-Cécile Fumey (Age 48)
    HR Director
  • Dr. Iman El-Hariry M.D. (Age 63)
    Ph.D., Chief Medical Officer
  • Ms. Karine Charton Ph.D.
    Director of Innovation & Valorization
  • Dr. Philip L. Lorenzi
    Consultant & Member of Scientific Board
  • Prof. Eric Raymond M.D.
    Ph.D., Consultant & Member of Scientific Board
  • Dr. Bridget Bax
    Consultant & Member of Scientific Board

Key Competitors

View All Competitors

ERYP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD).

When did ERYTECH Pharma IPO?

ERYTECH Pharma (ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.

This page (NASDAQ:ERYP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media